Alexion Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, is renowned for its innovative therapies in the field of rare diseases. Founded in 1992, Alexion has made significant strides in developing life-changing treatments, particularly in the areas of neurology, nephrology, and immunology. The company’s flagship products, including Soliris and Ultomiris, are unique in their ability to target complement-mediated diseases, setting new standards in patient care. With a strong market position, Alexion has achieved notable milestones, such as expanding its global reach across North America, Europe, and Asia. Committed to advancing science and improving patient outcomes, Alexion Pharmaceuticals continues to be a pivotal player in the biopharmaceutical industry.
We don't have data for Alexion Pharmaceuticals, Inc., but we can show you information about their parent organization instead.
View parent company